Although not all of these conditions were prespecified as AESIs in our phase III trial, these mentioned treatment-related AEs also occurred in patients receiving 24-week hetrombopag (n = 2, thromboembolic events, including one patient AMI and another with subclavian vein thrombosis; n = 27, increased alanine aminotransferase; n = 24, increased aspartate aminotransferase; n = 1, cataracts; n = 1, prolonged QT interval with QTc 469 ms; n = 2, graded MF 1/2 myelofibrosis), who were all cured or recovered after active treatments. This evidence concerns the gene GPT and cataract.